Ceilidh

Michael Zey
futurist3000@aol.com

In3 is designed as a forum for venture capitalists, investment bankers, and corporate business development executives to hear presentations from more than 50 emerging medical technology companies seeking funding, acquisition, and/or strategic partnerships.  Approximately 350 senior executives representing the major medical technology companies and investment firms will be in attendance.

"We are extremely pleased to have Professor Langer kick off our ninth In3 conference, and our third in Boston," said Sharon O'Reilly, President & CEO of Medtech Insight.  "After all, Professor Langer is one of the world's preeminent authorities in medical technology innovation, which is the pervading theme of this two-day event."

Robert S. Langer is the Kenneth J. Germeshausen Professor of Chemical and Biomedical Engineering at MIT.  Discover Magazine last year named Professor Langer as one of the 20 most important people in medical technology.  Also last year, Forbes selected Professor Langer as one of the 15 innovators worldwide who will reinvent our future.  Previously, Time and CNN named Professor Langer as one of the 100 most important people in the United States, and one of the 18 top people in science or medicine in the U.S.  In 1989, Professor Langer was elected to the Institute of Medicine of the National Academy of Sciences, and in 1992 he was elected to both the National Academy of Engineering and the National Academy of Sciences.  Professor Langer is one of a very select few persons ever elected to all three U.S. national academies and the youngest (at age 43) in history to ever receive this distinction.  His In3 keynote address will be entitled "Creating and Developing New Medical Technologies."

To date, 55 companies are confirmed to present at In3 Boston.  Each company will give a ten-minute presentation followed immediately by individual meetings in breakout rooms.  Presenters include: Acorn Cardiovascular, Actuality Systems, AgaMatrix, Agentase, ALung Technologies, Andromed, Angiogene, Aquamer, Biointerface, Biophan Technologies, Biowave, BodyMedia, CardioFocus, Comedicus, Confluent Surgical, Design & Performance Canada, Devax, Disc Dynamics, ECI Biotech, Endius, Ension, EP Limited, Eunoe, Florence Medical, Genomic Profiling Systems, Glucose Sensing Technologies, Hamilton Thorne Biosciences, Harbinger Medical, ImageGuide, Impliant, Integrated Endoscopy, Intelligent Medical Devices, Interventional Imaging, IntraLuminal Therapeutics, Light Sciences, Medihale, MR Instruments, N-Dia, Pelikan Technologies, Percardia, Physiometrix, Power Medical Interventions, QuestStar Medical, SleepUp, Spectrasonics Imaging, Spineology, Spiration, Tayside Flow Technologies, TheraCyte, Vascular BioSciences, Verimetra, Vertebron, Vertelink, Xilas Medical and Xillix Technologies.  An updated listing of presenters and other details can be viewed at www.medtechinsight.com/in3-09.html.

Event co-sponsors include: AdvaMed, Battelle, Clinsights, Hale and Dorr LLP, LyChron, Medmarc and The Hartford, Pittsburgh Life Sciences Greenhouse, PR Newswire, Reimbursement Principles, Ronald Trahan Associates Inc., The MedTech Group, Underwriters Laboratories, Windhover Information, and ZEVEX.

To register for this conference or for more information, call 949-219-0150, 888-290-2225 toll-free in the U.S., or by e-mail at in3@medtechinsight.com.  Visit Medtech Insight's website at www.medtechinsight.com to read more about the company's products and to download a sample newsletter issue.

SOURCE  Medtech Insight, LLC  

CO:  Medtech Insight, LLC

ST:  California, Massachusetts

SU:  TDS

Web site:  www.medtechinsight.com/in3-09.html

www.prnewswire.com
 
09/22/2003 08:02 EDT